KRAS and pachyonychia congenita: Exosomal KRAS mutations were detected in 66.7% (22/33), 80% (12/15), and 85% (17/20) of localized, locally advanced, and metastatic PC, respectively, and in 7.4% (4/54) of healthy controls in the discovery cohort.